PCSK9: Difference between revisions
Michal Harel (talk | contribs) New page: <StructureSection load='2w2m' size='350' side='right' caption='Structure of human PCSK9 complex with LDL receptor EGF-A domain (PDB entry 2w2m)' scene=''> '''PCSK9''' or '''Propr... |
Michal Harel (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
<StructureSection load='2w2m' size='350' side='right' caption='Structure of human PCSK9 catalytic domain (grey) and prodomain (green) complex with LDL receptor EGF-A domain (magenta) and Ca+2 ion (PDB entry [[2w2m]])' scene=''> | |||
<StructureSection load='2w2m' size='350' side='right' caption='Structure of human PCSK9 complex with LDL receptor EGF-A domain (PDB entry [[2w2m]])' scene=''> | |||
'''PCSK9''' or '''Proprotein Convertase Subtilisin/Kexin type 9''' is a proteinase which is an enzyme which is part of cholesterol synthesis. PCSK9 undergoes autocatalysis producing an active enzyme from its precursor. PCSK9 binds to EGF-A domain of the LDL receptor (LDLR) inducing its degradation. Low levels of LDL receptor are a cause of hypercholesterolemia since LDLR removes LDL cholesterol from the blood. Thus PCSK9 is an important drug target as its level affects the amount of cholesterol in blood. | '''PCSK9''' or '''Proprotein Convertase Subtilisin/Kexin type 9''' is a proteinase which is an enzyme which is part of cholesterol synthesis. PCSK9 undergoes autocatalysis producing an active enzyme from its precursor. PCSK9 binds to EGF-A domain of the LDL receptor (LDLR) inducing its degradation. Low levels of LDL receptor are a cause of hypercholesterolemia since LDLR removes LDL cholesterol from the blood. Thus PCSK9 is an important drug target as its level affects the amount of cholesterol in blood. | ||
Revision as of 10:10, 17 July 2013
<StructureSection load='2w2m' size='350' side='right' caption='Structure of human PCSK9 catalytic domain (grey) and prodomain (green) complex with LDL receptor EGF-A domain (magenta) and Ca+2 ion (PDB entry 2w2m)' scene=>
PCSK9 or Proprotein Convertase Subtilisin/Kexin type 9 is a proteinase which is an enzyme which is part of cholesterol synthesis. PCSK9 undergoes autocatalysis producing an active enzyme from its precursor. PCSK9 binds to EGF-A domain of the LDL receptor (LDLR) inducing its degradation. Low levels of LDL receptor are a cause of hypercholesterolemia since LDLR removes LDL cholesterol from the blood. Thus PCSK9 is an important drug target as its level affects the amount of cholesterol in blood.
3D structures of PCSK9
Updated on 17-July-2013
2p4e, 2pmw, 2qtw – hPCSK9 – human
3bps, 2w2m, 3gcx – hPCSK9 + LDLR EGF-A
2w2n, 3gcw – hPCSK9 + LDLR EGF-A (mutant)
2w2o, 2w2p, 2w2q – hPCSK9 (mutant) + LDLR EGF-A
3h42 – hPCSK9 (mutant) + antibody
2xtj, 3sqo, 4k8r – hPCSK9 + antibody
3m0c – hPCSK9 (mutant) + LDLR
3p5b, 3p5c – hPCSK9 + LDLR variant
